WednesdayApr 03, 2024 10:00 am

Spotlight on Disparities in Pediatric Healthcare Access

As of 2019, congenital heart defects affected roughly 1.3 million individuals in America. Mild heart defects are shown to present in at least eight of every one thousand babies. Experts believe that about one in four infants born with these defects need intervention in their first 12 months of life to survive. Now, new research has determined that children in heavily polluted areas classified as economically and socially deprived were almost 50% more likely to suffer from congenital heart defects as compared to those from less polluted and less deprived areas. This comes after research by the American Heart Association…

Continue Reading

TuesdayApr 02, 2024 9:00 am

Clene Inc. (NASDAQ: CLNN) Announces Publication of “Protein Corona Composition of Gold Nanocatalysts” in ACS Pharmacology & Translational Science

The publication provides a comprehensive analysis of proteins from human blood plasma that interact with CNM-Au8(R) CNM-Au8 nanocrystals coated with a protein corona are less prone to clumping compared to those without any coating Certain apolipoproteins found on the nanocrystals' surface, which aid in crossing the blood-brain barrier (“BBB”), were identified, suggesting an enhanced delivery mechanism into the brain The findings enrich the understanding of CNM-Au8's mechanism as preparations for a Phase 3 trial for ALS are underway, scheduled for the second half of 2024 Clene (NASDAQ: CLNN) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company…

Continue Reading

MondayApr 01, 2024 10:00 am

Prenatal Exposure to Caffeine and High-Fat Diets Heighten Autism Risk in Rodent Models

A new study has found that caffeine exposure during pregnancy and a high-fat diet following delivery considerably heightens the risk of autism-like behaviors, as observed in rodent models. Autism spectrum disorder is a developmental disorder that influences how individuals interact, behave, learn and communicate. Children with this condition may have trouble with social interactions as well as display repetitive behaviors, among other symptoms. Given that caffeine consumption and high-fat diets are widespread, it is important to understand possible risk factors and develop strategies to prevent the disorder’s development. For their study, the researchers divided pregnant rats into two groups, one…

Continue Reading

MondayApr 01, 2024 9:00 am

Sigyn Therapeutics Inc. (SIGY) CEO Discusses Company’s Blood Purification Therapies to Address Cancer and Other Life-Threatening Conditions at the Emerging Growth Conference

Sigyn Therapeutics CEO Jim Joyce reviewed the company’s pipeline of technologies, including ChemoPrep(TM), ChemoPure(TM), and ImmunePrep(TM) to improve patient responses to various cancer therapies, and Sigyn Therapy(TM) to address drug resistant viral and bacterial infections, endotoxemia, and sepsis, a leading cause of hospital deaths in the United States The company created Sigyn Therapy(TM) to treat pathogen-associated disorders that are not addressed with drug therapies Sigyn Therapeutics is developing ChemoPrep(TM) and ImmunePrep(TM), to improve patient responses to chemotherapy and immunotherapeutic antibodies, respectively To reduce toxicity, the company designed ChemoPure(TM) to sweep off-target chemotherapy from the bloodstream before it is able to cause the…

Continue Reading

ThursdayMar 28, 2024 9:45 am

Longeveron Inc. (NASDAQ: LGVN) Discusses 2023 Progress and 2024 Plans in Corporate Update

Longeveron recently released its full-year results for the period ended December 31, 2023, and provided a corporate update The update outlined the company’s plans to prioritize the development of Lomecel-B(TM) in Hypoplastic Left Heart Syndrome (“HLHS”), a rare, pediatric congenital heart condition characterized by an underdeveloped left side of the heart Longeveron plans to complete the enrollment in the ELPIS II trial for HLHS in 2024 The company also reported that it is exploring opportunities to advance its Alzheimer’s disease program through potential partnerships or other sources of funding Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing regenerative medicine for…

Continue Reading

ThursdayMar 28, 2024 9:00 am

Astrotech Corp. (NASDAQ: ASTC) and AgLAB Inc. Use Mass Spectrometer Technology to Significantly Enhance Hemp and Cannabis Production Yield and Profit

The cannabinoid market value in 2023 was $22.23 billion and is expected to grow at a CAGR of 15.3%, resulting in an estimated market value of $60.36 billion The global mass spectrometry market will reach $6.77 billion in 2024 and is expected to grow at a CAGR of 6.25%, reaching $9.17 billion by 2029. Astrotech and subsidiary AgLAB Inc. are using mass spectrometry to boost the profitable yield of hemp and cannabis production The United States has seen a rising awareness of the health and therapeutic benefits of cannabinoids, prompting an expected market increase of 15.3%, from $22.23 billion in…

Continue Reading

WednesdayMar 27, 2024 10:00 am

Researchers Link Type 2 Diabetes to Heightened Alzheimer’s Risk

Scientists at Texas A&M University have found evidence suggesting that there may be a link between Alzheimer’s disease risk and type 2 diabetes. This is backed by data from a separate study, which found that roughly 81% of individuals living with Alzheimer’s disease also have type 2 diabetes. Alzheimer’s is a progressive brain disorder that affects memory, thinking and behavior. The disorder is also a common cause of dementia, accounting for at least 60% of dementia cases. The scientists believe it’s possible that a high-fat diet may increase inflammation levels in the body, which could in turn heighten the risk…

Continue Reading

TuesdayMar 26, 2024 9:45 am

Astiva Health’s Innovative Strategies for Enhancing Senior Mobility and Independence

Astiva Health Inc. is pioneering transformative healthcare for seniors, with a focus on enhancing mobility and promoting independence. This innovative approach places a strong emphasis on seniors as active participants in their healthcare journey, representing a shift towards a more interactive and preventive model of care. Embracing Active Participation Central to Astiva Health's mission is empowering seniors to engage actively in their healthcare decisions, supporting their flourishing in later years. The CDC highlights physical activity's crucial role in preventing chronic diseases among seniors, noting that regular physical activity can significantly reduce health risks associated with inactivity (CDC, 2020). Tailored Exercise…

Continue Reading

TuesdayMar 26, 2024 9:00 am

Clene Inc. (NASDAQ: CLNN) Announces Operational Highlights for Lead Therapeutic Candidate for ALS and MS

Clene’s recently released 2023 financial and operational updates highlight the company’s developments for the treatment of amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis CNM-Au8(R) functions as a neuroprotective and remyelinating therapy in neurodegenerative diseases Recent data from the randomized, double-blind, placebo-controlled HEALEY-ALS Platform Trial and its open-label extension, reported by Clene in December 2023, revealed encouraging outcomes on survival and delayed clinical worsening Clene recently provided perspectives on its achievements and the development path for CNM-Au8(R) during its participation in the 36th Annual ROTH Conference, which was held March 18-19, 2024 Clene (NASDAQ: CLNN) and its wholly owned subsidiary Clene…

Continue Reading

MondayMar 25, 2024 10:00 am

New Study Leverages Real-World Data to Assess Differences in Parkinson’s Progression

Recent research assessed the differences in Parkinson’s disease progression between research populations and real-world data. Parkinson’s disease is a progressive disorder that affects the nervous system and body parts controlled by the nerves. Illness-modifying treatments haven’t been successful for Parkinson’s, with some therapies that have shown promise in trials failing at later stages. The primary challenge to developing illness-modifying treatments for this particular condition is the fact that molecular processes that drive pathogenesis haven’t been understood properly. Additionally, diverse ages on the condition’s onset and different progression patterns indicate heterogeneity. For their research, the scientists used Harvard Biomarkers studies and…

Continue Reading

Official NewsWire Relationships

BIO Informa DGE Dynamic Global Events DTC Healthcare Conference Kiasco Reasearch Nexus Conferences Octane

BioMedWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 415.949.5050